Scarica l'app Stockscreener
5.76
1.54%
-0.09
Dopo l'orario di chiusura:
5.70
-0.06
-1.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.5%Time to Sell? - MarketBeat
DiaMedica Therapeutics: Interesting Work In Treating Ischemic Stroke - Seeking Alpha
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$43m - Simply Wall St
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December - Defense World
Diamedica Stock Soars to 52-Week High, Hits $6.41 - Investing.com
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m - Yahoo Finance
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 12.2% - MarketBeat
Diamedica Stock Soars to 52-Week High, Reaching $5.74 - Investing.com
Diamedica Stock Soars to 52-Week High, Reaching $5.74 By Investing.com - Investing.com UK
DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% HigherHere's What Happened - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% Higher – Should You Buy? - Defense World
Amneal to Participate at Upcoming Investor Conferences - Business Wire
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia - BioSpace
DiaMedica Therapeutics management to meet virtually with Lake Street - Nasdaq
DiaMedica Forms Elite Scientific Advisory Board for Preeclampsia Treatment Development - StockTitan
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition - Business Wire
DMAC Stock Soars to 52-Week High, Hits $4.95 Amid Bullish Run - Investing.com
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation - Simply Wall St
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks
DMACDiaMedica Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - BioSpace
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - BioSpace
DiaMedica Launches Phase 2 Trial for Novel Preeclampsia Treatment DM199 - StockTitan
DiaMedica (DMAC) to Present at Craig-Hallum Conference: Spotlight on DM199 Stroke Treatment | DMAC Stock News - StockTitan
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Yahoo Finance
DiaMedica Therapeutics (DMAC) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
CRH plc (the "Company") Form 10-Q for the quarterly period ended September 30, 2024 - Business Wire
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - BioSpace
Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short Interest - MarketBeat
Best Momentum Stocks to Buy for October 14th - Yahoo Canada Finance
Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT) - Defense World
DiaMedica shares maintain Buy rating from H.C. Wainwright - Investing.com
DiaMedica shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial - Yahoo Finance
DiaMedica advances preeclampsia treatment with trial approval By Investing.com - Investing.com South Africa
DiaMedica advances preeclampsia treatment with trial approval - Investing.com India
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DiaMedica Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:DMAC) - MarketBeat
KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors - Business Wire
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment By Investing.com - Investing.com South Africa
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment - Investing.com India
DiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
DiaMedica: Readying For REDUX Readout - RTTNews
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):